Friday, December 11, 2009

Phase III Study Demonstrates INVEGA® SUSTENNA(TM) Statistically Similar to RISPERDAL® CONSTA® Long-Acting Injection


A December 10th news release from PR Newswire:
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

To read the entire news release, please click here

No comments: